Volume 3, Issue 3 And 4 (11-2016)                   vacres 2016, 3(3 And 4): 60-63 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Afrough P, Behrouzi A, Davari M, Malekan M, Fateh A, Vaziri F et al . Cloning and expression of porA gene as the first step of a vaccine candidate study against Neisseria meningitidis serogroup A infection. vacres 2016; 3 (3 and 4) :60-63
URL: http://vacres.pasteur.ac.ir/article-1-93-en.html
Mycobacteriology and Pulmonary Research Department, Pasteur Institute of Iran. Tehran, Iran. Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
Abstract:   (6241 Views)

Introduction: Neisseria meningitidis is a major causative agent of bacterial septicemia and meningitis in human. PorA is a major component of the outer membrane of N. meningitidis and functions as a cationic Porin. This study aimed to clone and determine the expression of PorA as the first step for producing a proper antigen in a vaccine study against N. meningitidis. Methods: An approximately 1200-bp fragment of porA gene was amplified by PCR using                  N. meningitidis serogroup A genomic DNA and then cloned into prokaryotic expression vector pET-28a. The resulting construct (pET28a-porA plasmid) was transformed into competent E.coli BL21 cells for expression of recombinant protein. The proper overexpression of the recombinant protein was verified by SDS-PAGE and Western Blotting. Results: Cloning of porA was confirmed by colony-PCR and enzymatic digestion. The nucleotide sequence homology of the cloned porA gene was 97% , compared to the reference gene (NCBI GenBank accession number AL157959.1). The prokaryotic expression system (pET28a-porA- BL21) could  produce our 45-kDa target recombinant protein, efficiently. Conclusion: The prokaryotic expression system and conditions used in this study provides an applicable method for producing recombinant PorA and possibly many other bacterial outer membrane proteins for future vaccine studies.

Full-Text [PDF 397 kb]   (1682 Downloads)    
Type of Study: Original article |
Received: 2017/04/15

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.